X

Download Cervical Cancer Free North Carolina PowerPoint Presentation

SlidesFinder-Advertising-Design.jpg

Login   OR  Register
X


Iframe embed code :



Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / Cervical Cancer Free North Carolina PowerPoint Presentation

Cervical Cancer Free North Carolina PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

PowerPoint is the world's most popular presentation software which can let you create professional Cervical Cancer Free North Carolina powerpoint presentation easily and in no time. This helps you give your presentation on Cervical Cancer Free North Carolina in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Cervical Cancer Free North Carolina powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

Slide 1 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention
Slide 2 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith
Slide 3 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear
Slide 4 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164
Slide 5 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types)
Slide 6 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females
Slide 7 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen
Slide 8 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164
Slide 9 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/
Slide 10 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99.
Slide 11 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.*
Slide 12 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level
Slide 13 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky
Slide 14 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   .
Slide 15 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas
Slide 16 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn
Slide 17 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool
Slide 18 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes
Slide 19 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith
Slide 20 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith How Can We Work Actively Together? January: Cervical Cancer Awareness Month is right around the corner.
Slide 21 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith How Can We Work Actively Together? January: Cervical Cancer Awareness Month is right around the corner.
 

Frequently Asked Questions

> About SlidesFinder?

Slidesfinder is a website that allows users to upload and share their PowerPoint presentations online. It provides a platform for individuals and businesses to share their ideas and knowledge through presentations, and for others to view and download these presentations for educational or professional purposes.
Slidesfinder offers a wide range of presentation topics and categories, including business, education, science, technology, health, and more. Users can also search for presentations using keywords, tags, or by category. The website provides tools to create professional presentations with rich media, animations, and graphics.



One of the key features of Slidesfinder is its user-friendly interface, which allows users to easily upload, view, and share presentations. Users can also embed their presentations in their websites or blogs using the website's embed code feature.
Slidesfinder also offers premium services, such as the ability to create private presentations and to download presentations in high-quality formats. However, the basic features of Slidesfinder are free to use, making it accessible to anyone who wants to share their ideas and knowledge through presentations.

> How do I register with SlidesFinder?

Go to registration page (you can see signup link on top of website page) https://www.slidesfinder.com/signup . If you have facebook/gmail account them just click on SIGN IN WITH FACEBOOK OR SIGN IN WITH GOOGLE button, by this you will be a registered member of slidesfinder without filling any form, required detail automatically will be fatch from your account. If you do not a Facebook account, then click on "Signup". Fill all required fields and you will be a registered member of slidesfinder.

> Is slidesfinder account confirmation is mandatory?

Yes it is mandetory to active your account to login.

> Do I need to signup/login on SlidesFinder before uploading a PowerPoint presentation?

Yes, you need to login with your account before uploading presentation. Your username will be displayed on your uploaded presentation. Your registered email id is needed for sending your stats of uploaded presentation.

Slidesfinder is a sharing website for PowerPoint presentations search and share. Find your interest in the form of powerpoint presentations on slidesfinder and save your valuable time . On Slidesfinder you get presentations from our huge library of professional ppt presentations. We believe in making your search INFORMATIVE and FUN. Find your best ppt presentation from a pool of PowerPoint presentations stacked under important industry categories like business & management, heath & Wellness,eduction & training etc. We provide unique informative PowerPoint presentation for marketers, presenters and educationists. These professional PowerPoint presentations are uploaded by professionals from across numerous industry segments.These ppt presentations are available for FREE download.

Not just finding your interest, but facilitate you broadcast your interest. We have created this platform for easy sharing of PowerPoint presentations, ensuring that these presentations get maximum exposure. Create your slidesfinder account and upload PowerPoint presentations for free, share on social media platforms and BUILD YOUR CROWD WITH PRESENTATION !!

The Great Buddha says, "Share your knowledge.It’s a way to achieve immortality"! So, start sharing knowledge and we are here to make that immortal !!

© 2013-2024 SlidesFinder. All rights reserved.

Re-productivity of content are not allowed. Without prior written permission from author, commercial use of any content is illegal.